Abivax Aktie [WKN DE: A14UQC / ISIN: FR0012333284]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Abivax SA

30.10.17		ABIVAX to Present at BIO-Europe® 2017 – 23rd Annual International Partnering Conference (Businesswire)
12.10.17		ABIVAX Presents Novel Data on the Efficacy of Its Immune Enhancer ABX196 in Animal Model of Liver Cancer at the World Vaccine Congress (Businesswire)
28.09.17		ABIVAX Secures an Equity Line Financing with Kepler Cheuvreux (Businesswire)
28.09.17		ABIVAX’s ABX464 Reduces HIV Reservoir in Blood in Second Phase 2a Clinical Trial (Businesswire)
20.09.17		ABIVAX First-Half 2017 Financial Results and Update (Businesswire)
20.09.17		ABIVAX receives French regulatory Approval to Begin Clinical Trial of ABX464 in Ulcerative Colitis (Businesswire)
18.09.17		ABIVAX: First Patient Dosed in Three-Month Cohort of Phase 2a Study of Oral ABX464 in HIV-Suppressed Patients (Businesswire)
11.09.17		ABIVAX Presents Full ABX464 Positive Phase 2A Clinical HIV Data at the HIV Cure and Reservoir Symposium (Businesswire)
07.09.17		ABIVAX and Evotec Enter into Strategic Collaboration to Develop Novel Antiviral Agents (Businesswire)
13.07.17		ABIVAX to Present Latest Clinical Data on ABX464 at the International Aids Society Conference in Paris, France (Businesswire)
02.05.17		ABIVAX Confirms Trading Resumption (Businesswire)
28.04.17		ABIVAX Confirms Trading Suspension (Businesswire)
09.01.17		ABIVAX to Receive €8.4 Million from Bpifrance "Invest in the Future Program” (PIA) for the Development of Innovative Antiviral Drugs (Businesswire)
15.12.16		ABIVAX Appoints Didier Blondel as Chief Financial Officer (Businesswire)
24.11.16		ABIVAX to Host Key Opinion Leader Luncheon for Investors Focused on Novel Approaches to HIV Therapy (Businesswire)
16.11.16		ABIVAX to Present Phase IIa Clinical Data on ABX464 During NIH/NIAID-Sponsored Strategies for an HIV Cure Meeting 2016 (Businesswire)
15.11.16		ABIVAX to Present at Upcoming Investors Conferences (Businesswire)
28.10.16		ABIVAX to Attend the Jefferies 2016 London Healthcare Conference (Businesswire)
27.10.16		ABIVAX presented this week new pre-clinical data on ABX464 during scientific conference on "HIV Drug Therapy” in Glasgow, Scotland (Businesswire)
11.10.16		ABIVAX Announces R&D Day at Company’s New Collaborative Laboratory in Montpellier (Businesswire)
04.10.16		ABIVAX: Publication of a shareholder newsletter (Businesswire)
20.09.16		ABIVAX Announces the Publication of Its 2016 Half-Year Financial Report (Businesswire)
20.09.16		ABIVAX Provides Corporate Update and Reports 2016 Half Year Financial Results (Businesswire)
13.09.16		ABIVAX Completes the Second Milestone in CaReNa, a "Strategic Industrial Innovation Project” Supported by Bpifrance (Businesswire)
06.07.16		ABIVAX: Half-Year Report on the Liquidity Contract at 30 June 2016 (Businesswire)
17.06.16		Analysis of Ongoing ABX203 Phase IIb/III Trial in Chronic Hepatitis B Virus Infection Shows Good Safety, but Primary Endpoint of Study is Unlikely to Be Reached (Businesswire)
03.06.16		ABIVAX: Combined Annual General Meeting: Availability of Supporting Documents (Businesswire)
30.05.16		Ongoing Clinical Development of ABX464: ABIVAX Launches ABX464-004 Study (Businesswire)
27.04.16		ABIVAX Abstract on ABX464 Selected for Presentation at the AIDS 2016 Conference in Durban, South Africa (Businesswire)
25.04.16		ABIVAX Enters into a Manufacturing Agreement with PCAS for ABX464, Thus Ensuring Drug Candidate Supply for Upcoming Clinical Trials (Businesswire)
19.04.16		ABIVAX Obtains Regulatory and Ethics Clearance in Spain to Begin Second Phase IIa Clinical Trial for ABX464 in HIV/AIDS Patients (Businesswire)
31.03.16		ABIVAX to Participate in the European Small-Cap Event in Paris on April 11-12, 2016 (Businesswire)
15.03.16		ABIVAX: 2015 Full-Year Results and Progress Report (Businesswire)
25.02.16		ABIVAX’s Novel Approach to Treat HIV Demonstrates Safety and Preliminary Anti-viral Activity in Phase IIa (Businesswire)
11.02.16		ABIVAX To Participate in the Upcoming RBC Capital Markets 2016 Healthcare Conference in New York, and in the Credit Suisse Healthcare Conference in London (Businesswire)
21.01.16		ABIVAX to Present at the Prestigious Conference on Retroviruses and Opportunistic Infections (CROI) Positive Top-Line Clinical Phase IIa Data for Novel HIV Drug-Candidate ABX464 (Businesswire)
11.01.16		ABIVAX announces positive top-line clinical Phase IIa data for novel HIV drug-candidate ABX464 (Businesswire)
08.01.16		ABIVAX: Half-Year Report on the Liquidity Contract at 31 December 2015 (Businesswire)
21.12.15		Abivax Completes Recruitment of ABX464 Phase IIa HIV Study (Businesswire)
17.12.15		ABIVAX to Present at the Biotech ShowcaseTM During the JP Morgan Healthcare Conference (Businesswire)
10.12.15		ABIVAX: 2016 Financial Calendar (Businesswire)
08.12.15		ABIVAX: ABX203 (HeberNasvac) Granted Cuban Marketing Authorization to Treat Chronic Hepatitis B (Businesswire)
30.11.15		ABIVAX Reports Healthy Volunteers Phase I Data for ABX464 (Businesswire)
24.11.15		ABIVAX to Celebrate World AIDS Day with an Update on the Development of Its HIV Therapeutic Candidate, ABX464 (Businesswire)
12.11.15		ABIVAX to Participate in the Upcoming Jefferies Global Healthcare Conference in London and the German Equity Forum in Frankfurt (Businesswire)
29.09.15		ABIVAX: Availability of the Half-Year Financial Report as of 30 June 2015 (Businesswire)
29.09.15		ABIVAX – 2015 Half-Year Results (Businesswire)
24.09.15		ABIVAX Completes Recruitment in Its Phase IIb/III Pivotal Study with ABX203, First-in-Class Therapeutic Vaccine Against Chronic Hepatitis B (Businesswire)
23.09.15		ABIVAX Strengthens Its Senior Leadership Team by Appointing Dr. Jean-Marc Steens, M.D. as the Company’s Chief Medical Officer (Businesswire)
15.09.15		ABIVAX Appoints Antonino Ligresti, MD and Dominique Costantini, MD to Its Board of Directors (Businesswire)

Zurück | 1 | 2 | 3 | 4 | Weiter

Newssuche

Meistgelesene Nachrichten

DeepSeek sorgt nur noch partiell für anhaltenden Schock: SoftBank-Aktien & Co. auf Talfahrt - NVIDIA nach Rekordverlust erholt

Negative Entwicklungen am Krypto-Markt: Wieso Bitcoin, Ethereum, Ripple & Co. nachgeben

Ausblick EZB-Entscheid: Kommt es zu einer erneuten Zinssenkung?

ASML-Aktie weit im Plus: ASML übertrifft Erwartungen mit neuem Umsatzrekord

US-Notenbank Fed verzichtet auf Zinsschritt

NVIDIA-Aktie verliert: Weitere Exportbeschränkungen?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	31.01.2025 06:41
Kaufwert:	EUR
	Hinzufügen Speichern